All In Biotech

NDA 202245 · Hikma

Codeine Sulfate

Codeine Sulfate · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2011

Jun 30, 2011

Approved uses

1

Original approval plus efficacy supplements

Registered trials

511

100 Phase 3, 26 recruiting

FAERS reports

3,309

2,121 serious, 799 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

No structured label for this application in openFDA. Older and discontinued products often have none.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 30, 2011 Original approval · Type 5 - New Formulation or New Manufacturer REMSLetterLabel
1 products under this application
  • CODEINE SULFATE · CODEINE SULFATE 30MG/5ML · SOLUTION, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Codeine" as an intervention, any sponsor and status, largest first.

All 511 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug hypersensitivity817
  • nausea506
  • drug ineffective400
  • malaise380
  • vomiting373
  • headache371
  • arthralgia363
  • diarrhoea352
  • dyspnoea338
  • fatigue310
  • cough309
  • pain286

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20048
20051
20071
200921
2010233
2011387
2012501
2013154
2014232
2015102
2016122
2017144
2018156
2019243
2020154
2021120
2022200
2023140
2024201
2025131
202658

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Codeine Sulfate (Codeine Sulfate)

2024 spending

$975K

Beneficiaries

3,876

14,814 claims

Per beneficiary

$252

$0.70 per unit

View as table
YearSpending
2020$1,157,073
2021$1,295,086
2022$1,271,668
2023$1,122,751
2024$975,101

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 819 on PubMed

Sponsor: Hikma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.